

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
August 6, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “Company”) received a notice from the National Medical Products Administration (the “NMPA”) approving an additional (fifth) indication for the Company’s self-developed Class 1 innovative drug, Ivarmacitinib Sulfate Tablets (SHR0302 tablets). The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Ivarmacitinib Sulfate Tablets

Dosage Form: Tablet

Strength: 4mg

Registration Category: Chemical Drug Class 2.4

Acceptance No.: CXHS2500141

Prescription Drug/Over-the-Counter Drug: Prescription drug

Approved Indications: This product is indicated for adult patients with active non-radiographic axial spondyloarthritis who have had an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) and who have objective signs of inflammation (as evidenced by elevated C-reactive protein [CRP] and/or abnormal magnetic resonance imaging [MRI]).

II. The Approved Indications of the Drug

Ivarmacitinib Sulfate tablets had previously been approved for marketing in China for four indications, namely: 1. For the treatment of adult patients with active ankylosing spondylitis who have an inadequate response or intolerance to one or more TNF inhibitors. 2. For the treatment of adult patients with moderate to severe active rheumatoid arthritis who have an inadequate response or intolerance to one or more TNF inhibitors. 3. For the treatment of adult patients with moderate to severe atopic dermatitis who have an inadequate response or intolerance to topical therapies or other systemic treatments. 4. For the treatment of adult patients with severe alopecia areata.

After approval of this new indication, the product has achieved coverage of oral targeted management across the full disease spectrum of axial spondyloarthritis.

III. Other Information of the Drug

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton, with enthesitis as an important pathological feature. Based on whether definite sacroiliitis is present on X-ray, axSpA is classified into ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Approximately 10% of patients with non-radiographic axial spondyloarthritis progress to ankylosing spondylitis within 2 years ^[2,3].

The treatment goals for non-radiographic axial spondyloarthritis are to control symptoms and inflammation, prevent or delay structural damage, and improve patients' quality of life as much as possible. The current Chinese Guideline for the Diagnosis and Treatment of Non-Radiographic Axial Spondyloarthritis (2024 Edition) ^[2] recommends NSAIDs as the first-line pharmacological treatment for active non-radiographic axial spondyloarthritis. However, studies have shown that although symptoms may improve after adequate treatment, objective inflammatory markers may not show a significant concurrent improvement, and some patients have difficulty maintaining long-term medication adherence ^[4,5]. For patients with an inadequate response or intolerance to NSAIDs and objective evidence of inflammation, the guidelines recommend JAK inhibitors as one of the targeted treatment options ^[2,3].

Ivarmacitinib Sulfate Tablet is a highly selective JAK1 inhibitor that exerts anti-inflammatory and immunosuppressive biological effects by inhibiting JAK1 signaling

pathways. The approval of this new indication was based on a multicenter, randomized, double-blind, placebo-controlled pivotal phase III study (SHR0302-305). The study was conducted across 47 research centers nationwide and enrolled 304 adult patients with active non-radiographic axial spondyloarthritis who had an inadequate response or intolerance to NSAIDs. The relevant data were presented as an oral presentation at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress ^[1].

For non-radiographic axial spondyloarthritis, the oral medication of the same class, AbbVie's upadacitinib extended-release tablets (RINVOQ®), has been approved for marketing globally; however, no domestically developed JAK1 inhibitors from Chinese companies have yet been approved for marketing. According to the EvaluatePharma database, the global sales of upadacitinib extended-release tablets were approximately USD 8.304 billion in 2025. As of now, the cumulative R&D investment in projects related to Ivarmacitinib Sulfate amounts to approximately RMB 1,234.80 million (unaudited).

IV. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

August 6, 2026

[1] Zhang X, et al. Ivarmacitinib, a selective JAK1 inhibitor, in active non-radiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. 2026 EULAR, OP0237.

[2] Rheumatology Branch of the Chinese Medical Association, Rheumatology and Immunology Professional Committee of China Primary Health Care Foundation. Guideline for the diagnosis and treatment of non-radiographic axial spondyloarthritis (2024 edition)[J]. National Medical Journal of China, 2025, 105(13): 981-1003.

- [3] Dai SM, Xu H, Zhao Y, et al. Chinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis. *Autoimmunity Reviews*. 2026;25:104039.
- [4] Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. *Rheumatology (Oxford)*. 2017;56(1):95-102.
- [5] Varkas G, Jans L, Cypers H, et al. Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints. *Arthritis Rheumatology*. 2016;68(3):672-678.